Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Biofrontera ( (BFRI) ) has shared an update.
On May 8, 2025, Biofrontera Inc. received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement, as its stock had closed below $1.00 per share for 33 consecutive business days. The company has until November 5, 2025, to regain compliance by ensuring its stock price meets the minimum requirement for 10 consecutive business days. Biofrontera is actively monitoring its stock price and considering options to address the deficiency, although there is no guarantee of compliance.
The most recent analyst rating on (BFRI) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Biofrontera stock, see the BFRI Stock Forecast page.
Spark’s Take on BFRI Stock
According to Spark, TipRanks’ AI Analyst, BFRI is a Neutral.
Biofrontera’s score reflects its revenue growth and strategic milestones, such as FDA approvals and improved EBITDA, which provide a positive outlook. However, significant challenges remain, including ongoing unprofitability, high leverage, and weak technical indicators. These issues weigh heavily on the overall score, indicating potential risks that investors should consider.
To see Spark’s full report on BFRI stock, click here.
More about Biofrontera
Biofrontera Inc. is a Delaware-based corporation operating in the biotechnology industry, focusing on the development and commercialization of dermatological products.
Average Trading Volume: 87,185
Technical Sentiment Signal: Sell
Current Market Cap: $6.45M
For detailed information about BFRI stock, go to TipRanks’ Stock Analysis page.